News
Texas sues, accusing Eli Lilly of 'bribing' physicians to prescribe Zepbound, Mounjaro and other drugs
Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as administrative support services that helped providers process insurance claims.
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...
Eli Lilly is launching more supply of its weight loss drug Zepbound. The new single-dose vials will be priced lower than "all other incretin GLP-1 medicines for obesity." ...
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.
Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback